×
App Icon
The Standard e-Paper
Home To Bold Columnists
★★★★ - on Play Store
Download App

Europe's oncologists back biosimilar versions of cancer drugs

[PHOTO: COURTESY]

Europe's leading association of oncologists has thrown its weight behind cheaper copycat versions of biotech cancer drugs that have lost patent protection, saying they are effective and affordable.

Off-patent chemical medicines have for decades been copied with precision and sold as cheap generic versions, but drug regulators have only over recent years embraced copycat versions of complex biological drugs, known as biosimilars.

Get Full Access for Ksh299/Week.
Fact‑first reporting that puts you at the heart of the newsroom. Subscribe for full access.
  • Unlimited access to all premium content
  • Uninterrupted ad-free browsing experience
  • Mobile-optimized reading experience
  • Weekly Newsletters
  • MPesa, Airtel Money and Cards accepted
Already a subscriber? Log in